Antimicrobial Stewardship

Latest News


Latest Videos


Shorts

How AI Works in Drug Discovery
0:46
How AI Works in Drug Discovery
6 months ago
by
Akhila Kosaraju, MD(+1 more)
Paul Offit short
1:05
Advocating for the PASTEUR Act
8 months ago
by
Amanda Jezek(+1 more)
Adoption of Rapid Diagnostic Tools, Susceptibility Testing for Gram-Negative Infections
0:36
Vaccines as a Secondary Strategy in the Fight Against Antimicrobial Resistance
a year ago
by
Barry Kreiswirth, PhD(+1 more)
Adoption of Rapid Diagnostic Tools, Susceptibility Testing for Gram-Negative Infections
0:52
Adoption of Rapid Diagnostic Tools, Susceptibility Testing for Gram-Negative Infections
a year ago
by
Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; and Ryan P. McNamara, PhD(+1 more)
Ryan Shields, PharmD, MS, explains prescribing newer antibiotics for gram-negative infections: education gaps, limited evidence, costs; stresses real-world data, comparative effectiveness, sulbactam-durlobactam.
0:28
Clinical Considerations for Using Newer Antibiotics for Gram-Negative Infections
a year ago
by
Ryan K. Shields, PharmD, MS(+1 more)

Podcasts


CME Content


More News

Preclinical findings demonstrate that the novel efflux pump inhibitor TXA14007 significantly enhances azithromycin activity against multidrug-resistant Gram-negative bacteria, supporting a potential new oral treatment strategy for difficult-to-treat infections. Jesus Rosado-Lugo, PhD, offers insights on the study at ASM Microbe 2026.

The American Society for Microbiology (ASM) is leveraging its new phage therapy coordination efforts to connect researchers and clinicians, standardize approaches, and explore how bacteriophages could complement antibiotics in the fight against antimicrobial resistance. Colleen Kraft, MD, offers some insights on the organization's plans to help grow this medical modality.

The growing incidence of resistant Gram-negative infections in hospitals is being fueled by evolving resistance mechanisms, antibiotic overuse, and the rapid global spread of mobile genetic elements. Mariana Castanheira, PhD, FIDSA, FAAM, chief scientific officer at JMI Laboratories, discusses this topic and an agent with utility against pathogens carrying Metallo-beta-lactamases (MBLs).

Eolas Medical has an AI-powered clinical platform looking to aid health care professionals in accessing localized antimicrobial guidelines instantly, improving prescribing accuracy, reducing errors, and strengthening patient safety. CEO Declan Kelly, MBBS, provides insights on the platform and how his company is trying to address gaps in antimicrobial stewardship.